Information  X 
Enter a valid email address

Lifeline Scientific (LSI)

  Print      Mail a friend

Wednesday 20 March, 2013

Lifeline Scientific

Change of Adviser

RNS Number : 3912A
Lifeline Scientific, Inc
20 March 2013
 



 

20 March 2013

 

Lifeline Scientific, Inc.
("Lifeline" or the "Company")

 

Change of Advisor

 

 

 

Lifeline Scientific, the medical technology company, is pleased to announce the appointment of Panmure Gordon (UK) Limited as Nominated Adviser and Broker with immediate effect.

 

 

For further information:

 

Lifeline Scientific, Inc.


Tel: +1 847-294-0300

David Kravitz, CEO



 

 


Panmure Gordon (UK) Limited


Tel: +44 20 7886 2500

Freddy Crossley / Ben Roberts (Corporate Finance)



Adam Pollock / Victoria Boxall (Corporate Broking)






FTI Consulting


Tel: +44 20 7831 3113

Simon Conway / John Dineen



 

 

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to provide improved kidney preservation, evaluation and transport prior to transplantation. Today, it is widely recognised as the world's leading machine preservation device for kidneys. Employed by surgeons in over 135 leading transplant programmes in 23 countries worldwide, LifePorts have successfully preserved over 38,000 kidneys intended for clinical transplant. The product provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimise damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, LifePort records data on temperature, flow rate, vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant. LifePort is the only system with clinical outcomes data produced from an independent, prospective, randomised, statistically powered, multi-centre clinical trial. Study results have been widely published in scientific journals, including the New England Journal of Medicine. Data indicates that patients receiving LifePort preserved kidneys experienced significant reduction in the incidence and duration of delayed graft function and increased graft survival at 1-year and 3-years post-transplant. LifePort has also been recognised for its design and engineering. It has received prominent awards for design excellence from the medical device industry, has been selected for exhibition at the Smithsonian Cooper-Hewitt, National Design Museum and is part of the permanent Collection of The Museum of Modern Art (MoMA) in New York City.

 

About Lifeline Scientific, Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product is the FDA cleared, CE marked and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart, and lung are in late stage pre-clinical development.

For further information, please visit Lifeline Scientific's website at www.lifeline-scientific.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPBRGDXSSBBGXC